Evidence map›Paper›PMID 35717174›Full record

ArticleBMC public health2022

Characterization of test positivity among patients with coronavirus disease 2019 (COVID-19) in three electronic health records databases, February-November 2020.

Patrick Saunders-Hastings, Cindy Ke Zhou, Shayan Hobbi, Hui-Lee Wong, Patricia Lloyd, Eva Boyd, Nader Alawar, Tainya C Clarke, Jeff Beers, Timothy Burrell and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Patrick Saunders-HastingsGevity Consulting Inc., part of Accenture, Ottawa, ON, Canada. p.saunders.hastings@accenture.com.
Cindy Ke ZhouCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Shayan HobbiIBM Consulting, Bethesda, MD, USA.
Hui-Lee WongCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Patricia LloydCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Eva BoydGevity Consulting Inc., part of Accenture, Ottawa, ON, Canada.
Nader AlawarIBM Consulting, Bethesda, MD, USA.
Tainya C ClarkeCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Jeff BeersIBM Consulting, Bethesda, MD, USA.
Timothy BurrellIBM Watson Health, Cambridge, MA, USA.
Azadeh ShoaibiCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Center for Biologics Evaluation and Research · USIBM (United States) · USUnited States Food and Drug Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonitoring COVID-19 testing volumes and test positivity is an integral part of the response to the pandemic. We described the characteristics of individuals who were tested and tested positive for SARS-CoV-2 during the pre-vaccine phase of the pandemic in the United States (U.S.).

methodsThis descriptive study analyzed three U.S. electronic health record (EHR) databases (Explorys, Academic Health System, and OneFlorida) between February and November 2020, identifying patients who received an interpretable nucleic acid amplification test (NAAT) result. Test-level data were used to characterize the settings in which tests were administered. Patient-level data were used to calculate test positivity rates and characterize the demographics, comorbidities, and hospitalization rates of COVID-19-positive patients.

resultsOver 40% of tests were conducted in outpatient care settings, with a median time between test order and result of 0-1 day for most settings. Patients tested were mostly female (55.6-57.7%), 18-44 years of age (33.9-41.2%), and Caucasian (44.0-66.7%). The overall test positivity rate was 13.0% in Explorys, 8.0% in Academic Health System, and 8.9% in OneFlorida. The proportion of patients hospitalized within 14 days of a positive COVID-19 NAAT result was 24.2-33.1% across databases, with patients over 75 years demonstrating the highest hospitalization rates (46.7-69.7% of positive tests).

conclusionsThis analysis of COVID-19 testing volume and positivity patterns across three large EHR databases provides insight into the characteristics of COVID-19-tested, COVID-19-test-positive, and hospitalized COVID-19-test-positive patients during the early phase of the pandemic in the U.S.

Indexed as

COVID-19COVID-19 TestingElectronic Health RecordsFemaleHumansMalePandemicsSARS-CoV-2COVID-19EHRTest positivity

Identifiers

PMID35717174
PMCPMC9206507
OpenAlexW4283119365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.